Tower Research Capital LLC (Trc) Tcr2 Therapeutics Inc. Transaction History

Tower Research Capital LLC (Trc)

  • $5.8 Billion
  • Q2 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023
BUY
$1.0 - $1.62 $741 - $1,200
741 Added 10.68%
7,678 $11,000
Q4 2022

Feb 10, 2023
BUY
$0.83 - $1.44 $2,637 - $4,576
3,178 Added 84.54%
6,937 $7,000
Q3 2022

Nov 10, 2022
SELL
$1.86 - $3.75 $5,520 - $11,130
-2,968 Reduced 44.12%
3,759 $7,000
Q2 2022

Aug 15, 2022
SELL
$2.11 - $2.94 $6,264 - $8,728
-2,969 Reduced 30.62%
6,727 $19,000
Q1 2022

May 12, 2022
SELL
$2.4 - $4.71 $18,580 - $36,464
-7,742 Reduced 44.4%
9,696 $27,000
Q4 2021

Feb 14, 2022
BUY
$4.58 - $8.34 $44,357 - $80,772
9,685 Added 124.92%
17,438 $81,000
Q3 2021

Nov 15, 2021
BUY
$8.44 - $18.35 $42,714 - $92,869
5,061 Added 188.0%
7,753 $66,000
Q2 2021

Aug 16, 2021
BUY
$16.41 - $24.71 $6,974 - $10,501
425 Added 18.75%
2,692 $44,000
Q1 2021

May 17, 2021
BUY
$20.38 - $34.07 $27,451 - $45,892
1,347 Added 146.41%
2,267 $50,000
Q4 2020

Feb 16, 2021
SELL
$19.0 - $32.63 $334,552 - $574,549
-17,608 Reduced 95.03%
920 $28,000
Q3 2020

Nov 16, 2020
BUY
$13.1 - $20.69 $209,979 - $331,640
16,029 Added 641.42%
18,528 $376,000
Q2 2020

Aug 13, 2020
BUY
$6.51 - $16.85 $3,541 - $9,166
544 Added 27.83%
2,499 $38,000
Q1 2020

May 15, 2020
SELL
$6.01 - $16.01 $2,500 - $6,660
-416 Reduced 17.55%
1,955 $15,000
Q4 2019

Feb 07, 2020
BUY
$12.17 - $17.88 $25,337 - $37,226
2,082 Added 720.42%
2,371 $34,000
Q3 2019

Nov 05, 2019
SELL
$10.15 - $19.53 $11,022 - $21,209
-1,086 Reduced 78.98%
289 $4,000
Q2 2019

Aug 13, 2019
BUY
$13.64 - $20.97 $4,010 - $6,165
294 Added 27.2%
1,375 $20,000
Q1 2019

May 14, 2019
BUY
$15.01 - $22.15 $16,225 - $23,944
1,081 New
1,081 $19,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email